Thank you very much, and I will try to be brief in my answer, too.
We have been working extensively with a number of partners. I think we've all understood from the situation that it is no one area of government or one sector that can handle all of this. We worked with industry to make sure that we get the best notification we can in terms of where they see potential drug shortages or where they see potential disruptions in supply.
We worked with the provinces and territories very specifically to deal with some of the areas that were raised in the motion and in the recommendations from this committee in terms of looking for how we work together and how we get the best clinical information on the use of therapeutic alternatives.
We worked very much with the provinces and territories to try to provide some of those alternatives, for example.